ArticleDiscover oncology2025
Predictive value of immunomodulatory-related genes for the prognosis of lung adenocarcinoma based on bioinformatics analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lung adenocarcinoma (LUAD), characterized by its heterogeneity and high invasiveness, remains a challenging disease despite significant advancements in immunotherapy. Our study aimed to elucidate the expression differences of immunomodulatory-related genes in LUAD tissues compared to normal tissues and to validate the predictive role of these genes in the diagnosis, immunotherapy, and prognostic assessment of LUAD. Gene expression profiles and clinical data were extracted from TCGA and GEO datasets. GO analysis, KEGG pathway analysis, and GSEA were employed to identify biological process disparities. The single-sample Gene Set Enrichment Analysis (ssGSEA) was used to assess immune cell infiltration in distinct LUAD disease subtypes and derive an immunomodulatory score (Is) for patients with LUAD. Univariate and multivariate Cox regression analyses were performed to ascertain the prognostic significance of immunomodulatory-related genes (IRGs) in LUAD. Calibration curves and decision curve analysis (DCA) was used to verify the predictive efficacy of these IRs for the prognosis of patients with LUAD. This study identified, in the TCGA dataset, 18 IRGs that were differentially expressed between the LUAD and normal groups. Differential expression analysis IRGs using a threshold of |logFC|> 1 with an adjusted P-value < 0.05. GO and KEGG enrichment analysis, as well as GSEA results, revealed several significantly upregulated signaling pathways, including oxidative-stress-induced cell senescence and cell response to hypoxia. Interestingly, a strong correlation was observed between IRGs and activated dendritic cells in the four LUAD disease subtypes. Cox regression analyses demonstrated that the clinical prognosis of patients with LUAD was significantly associated with several key prognostic genes and clinical variables, including T, N, and M stages. The calibration curve and DCA verify this result. In summary, IRGs are increasingly being recognized for their pivotal roles in LUAD progression. The LUAD disease subtypes and Is derived from the IRGs offer valuable tools for predicting immunotherapy prognosis and stratifying the LUAD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.